Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center Open-label Phase I Study of ALT-801 for ex vivo Maturation and in vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Next Previous
X
Search
Trial Profile

A Single-center Open-label Phase I Study of ALT-801 for ex vivo Maturation and in vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine, and G-CSF in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALT 801 (Primary) ; Cytarabine; Fludarabine; Lymphokine-activated killer cells
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors Altor BioScience Corporation

    • Most Recent Events

    • 24 Nov 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by M.D. Anderson Cancer Center.
    • 25 Nov 2011 Actual trial start date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 25 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top